Summary
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Central Nervous System, Dermatology, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Transplant Rejection, Lymphoma, Ovarian Cancer, Bladder Cancer, Breast Cancer, Crohn's Disease (Regional Enteritis), Esophageal Cancer, Lupus Nephritis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Myasthenia Gravis, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Cervical Cancer, Colorectal Cancer, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Graft Versus Host Disease (GVHD), Graves Diseases, Head And Neck Cancer, Heart Transplant Rejection, Hepatic (Liver) Tumor, Hidradenitis Suppurativa, Hyperthyroidism, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liposarcoma, Liver Transplant Rejection, Malignant Mesothelioma, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Pediatric Diffuse Intrinsic Pontine Glioma, Pemphigus, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development
AbbVie Inc
Apexigen Inc
Apogenix AG
Avacta Life Sciences Ltd
BioNTech SE
Boehringer Ingelheim GmbH
Celldex Therapeutics Inc
Denceptor Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Kyowa Hakko Kirin Co Ltd
MedImmune LLC
Molecular Partners AG
Novartis AG
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles
ABBV-428 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABBV-927 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APG-1233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-005M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-655064 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Agonize CD40 and 4-1BB for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bleselumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-1140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNP-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FFP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iscalimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-7107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KGYY-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPL-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-5083 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MegaCD40L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize CD40 and Antagonize FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Target CD40 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Target FAP and CD40 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selicrelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selicrelumab + vanucizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UltraCD40L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones
Featured News & Press Releases
Jan 29, 2019: Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer
Nov 09, 2018: Celldex presents promising interim data from phase 1 study of differentiated CD40 agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Nov 06, 2018: Molecular Partners to present data on DARPin immuno-oncology compound FAP x CD40 at upcoming scientific conferences
Oct 11, 2018: Preclinical efficacy data of Apogenix HERA-CD40L published in Journal of Immunotherapy
May 18, 2018: Apexigen Expands Leadership Team with Appointment of Frances Rena Bahjat, Vice President, Discovery Research
Apr 20, 2018: Celldex Therapeutics presents data on CDX-1140 at AACR Annual Meeting 2018
Jan 03, 2018: Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013
Nov 30, 2017: Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
Nov 07, 2017: Results from Alligator Biosciences clinical phase I study support further clinical development of ADC-1013
Oct 31, 2017: Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer Annual Meeting
Oct 25, 2017: Apexigen Announces New Collaboration with UCSF
Sep 21, 2017: Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017
Sep 20, 2017: The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy
Jul 17, 2017: Apexigen Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors
May 10, 2017: Boehringer Ingelheim Phase II trial Now Enrolling Patients with the Kidney Disease Lupus Nephritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AbbVie Inc, H1 2019
Pipeline by Apexigen Inc, H1 2019
Pipeline by Apogenix AG, H1 2019
Pipeline by Avacta Life Sciences Ltd, H1 2019
Pipeline by BioNTech SE, H1 2019
Pipeline by Boehringer Ingelheim GmbH, H1 2019
Pipeline by Celldex Therapeutics Inc, H1 2019
Pipeline by Denceptor Therapeutics Ltd, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Johnson & Johnson, H1 2019
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2019
Pipeline by MedImmune LLC, H1 2019
Pipeline by Molecular Partners AG, H1 2019
Pipeline by Novartis AG, H1 2019
Dormant Products, H1 2019
Discontinued Products, H1 2019
List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
